Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by SYNAPS Dx

SYNAPS Dx Announces Prestigious Scientific Advisory Board to Guide Strategy and Commercialization of DISCERN™, Only Autopsy-Validated Test for Accurate Diagnosis of Alzheimer's Disease
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Observes November as National Alzheimer’s Disease Awareness Month and National Family Caregivers Month: Honoring Those Impacted by Alzheimer’s
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Observes September as World Alzheimer’s Month and Healthy Aging Month: Celebrates Researchers, Providers and Patients
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Releases Autopsy-Confirmed Results for DISCERN™ Alzheimer’s Test and Physicians’ Assessment of Clinical Utility of DISCERN at BRAINWeek 2023
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN™ Alzheimer’s Test and Physicians’ Assessment of the Clinical Utility of DISCERN at BRAINWeek 2023
From SYNAPS Dx
Via Business Wire
SYNAPS Dx DISCERN™ Test Provides Accurate Diagnosis of Alzheimer’s Disease, Optimizes Prescribing, Minimizes Patient Risks and Informs Coverage Decisions for Leqembi™
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Honors Alzheimer’s & Brain Awareness Month: Highlights Value of DISCERN™ as Only Skin Test to Accurately Diagnose Alzheimer’s Disease
From SYNAPS Dx
Via Business Wire
Study Confirms DISCERN™ Alzheimer’s Disease Diagnostic Projected to Save Nearly $5 Million Over Three Years for Medicare Advantage Plans, Avoids Inappropriate Prescribing of New, Expensive Medications
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Resolves Alzheimer’s Disease Diagnostic Dilemma: White Paper Documents Improved Diagnostic Pathway with Highly Accurate, Accessible Skin Test
From SYNAPS Dx
Via Business Wire
SYNAPS Dx President & CEO, Frank Amato, Named Life Sciences CEO of the Year in Maryland Tech Council 2023 ICON Awards
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Documents Need for Highly Accurate, Accessible and Non-invasive Alzheimer’s Disease Diagnostic as Alternative to Blood-Based Biomarkers
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Brings El Paso, Texas Marketplace First Highly Accurate Diagnostic Alzheimer’s Disease Test for Patients Diagnosed with Dementia
From SYNAPS Dx
Via Business Wire
Annals of Clinical Cytology and Pathology Publishes SYNAPS Dx Study, 90% of Physicians Follow Results of DISCERN™, First Highly Accurate Skin Test for Alzheimer’s Disease
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Demonstrates Physician Burden in Diagnosing Alzheimer's Disease, Value of Highly Accurate Diagnostic Test
From SYNAPS Dx
Via Business Wire
Early, Accurate Diagnosis of Alzheimer’s Disease with DISCERN™ Test is Critical for Identifying Appropriate Patients for Prescribing and Coverage of LEQEMBI™
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Releases Positive Budget Impact Results for DISCERNTM at International Conference on Aging Diseases and Elderly Care: Alzheimer’s Disease Diagnostic Projected to Save $4+ Million in Three Years
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Honors Caregivers, Patients and Families During Caregivers and Alzheimer's Awareness Months
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Publishes First Autopsy-Confirmed Results for Identifying Alzheimer’s in Presence of Other Co-Morbid Pathologies Using DISCERNTM Test
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Selects FrontRunner Health Care
From SYNAPS Dx
Via Business Wire
SYNAPS Dx’s DISCERN™ Diagnostic Test Supports Payer Coverage and Prescribing Decisions for Lecanemab, Expected Breakthrough Treatment of Alzheimer’s Disease
From SYNAPS Dx
Via Business Wire
SYNAPS Dx CEO Frank Amato Presents at HolonIQ, New York: Addresses Importance of Accurately Detecting Causes of Dementia Including Alzheimer’s Disease
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Honors Researchers, Providers, Patients and Families During World Alzheimer’s Month
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Opens High-Tech Laboratory Supporting Research & Commercialization of DISCERN, Highly Accurate, Minimally Invasive Alzheimer’s Disease Diagnostic Test
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Releases Autopsy-Confirmed Results for DISCERN Alzheimer’s Test MI Biomarker, Accurately Diagnoses Alzheimer’s in Presence of Other Co-Morbid Pathologies
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Showcases Autopsy-Confirmed Results for DISCERN Alzheimer’s Test MI Biomarker, For Identifying Alzheimer’s in Presence of Other Co-Morbid Pathologies
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Selects Dallas/Fort Worth Texas Markets as First Regions for National Commercialization of Highly Accurate Diagnostic Alzheimer’s Disease Test for Patients with Dementia Diagnosis
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Highlights Alzheimer’s & Brain Awareness Month in June, Offers First Skin Test for Diagnosing Alzheimer’s Disease
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Presents at ISPOR Annual Conference, Demonstrates 90% of Physicians Follow Results of DISCERN, First Skin Test for Alzheimer’s Disease
From SYNAPS Dx
Via Business Wire
SYNAPS Dx Partners with Millennial Caregiver App I-Ally: Expands Awareness of Early, Differential Diagnosis of Alzheimer’s Disease, Empowers Care Decision-Making
From SYNAPS Dx
Via Business Wire
SYNAPS Dx DISCERN Provides First-to-Market Definitive Diagnostic Test for Alzheimer’s Disease, Supports Payer Treatment Decisions, Releases Paper Authored by Advisory Council
From SYNAPS Dx
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.